9.32
0.42 (4.72%)
| Penutupan Terdahulu | 8.90 |
| Buka | 8.93 |
| Jumlah Dagangan | 2,342,506 |
| Purata Dagangan (3B) | 1,430,919 |
| Modal Pasaran | 1,199,083,264 |
| Harga / Jualan (P/S) | 1.79 |
| Harga / Buku (P/B) | 1.33 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2025 |
| Margin Keuntungan | -11.92% |
| Margin Operasi (TTM) | -9.24% |
| EPS Cair (TTM) | -0.620 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 67.08% |
| Nisbah Semasa (MRQ) | 1.98 |
| Aliran Tunai Operasi (OCF TTM) | 7.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.21 M |
| Pulangan Atas Aset (ROA TTM) | -2.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | NeoGenomics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 2.63 |
|
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.07% |
| % Dimiliki oleh Institusi | 102.29% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 18.00 (Piper Sandler, 93.13%) | Beli |
| 18.00 (Needham, 93.13%) | Beli | |
| Median | 17.00 (82.40%) | |
| Rendah | 15.00 (Goldman Sachs, 60.94%) | Beli |
| Purata | 16.75 (79.72%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 11.35 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Goldman Sachs | 17 Apr 2025 | 15.00 (60.94%) | Beli | 9.55 |
| 28 Jan 2025 | 18.00 (93.13%) | Beli | 15.18 | |
| Piper Sandler | 26 Feb 2025 | 18.00 (93.13%) | Beli | 10.40 |
| B of A Securities | 19 Feb 2025 | 16.00 (71.67%) | Pegang | 12.72 |
| Needham | 19 Feb 2025 | 18.00 (93.13%) | Beli | 12.72 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Apr 2025 | Pengumuman | NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting |
| 08 Apr 2025 | Pengumuman | NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 |
| 07 Apr 2025 | Pengumuman | NeoGenomics Completes Acquisition of Pathline |
| 01 Apr 2025 | Pengumuman | Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics |
| 18 Mar 2025 | Pengumuman | NeoGenomics Appoints Warren Stone as President & Chief Operating Officer |
| 10 Mar 2025 | Pengumuman | NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline |
| 24 Feb 2025 | Pengumuman | NeoGenomics to Participate in Upcoming Investor Conferences |
| 18 Feb 2025 | Pengumuman | NeoGenomics Reports Fourth Quarter and Full Year 2024 Results |
| 30 Jan 2025 | Pengumuman | PacBio Announces Appointment of Chris Smith to Board of Directors |
| 29 Jan 2025 | Pengumuman | NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |